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ABSTRACT
Trypanosoma brucei causes human African try-
panosomiasis and regularly switches its major sur-
face antigen, VSG, in the bloodstream of its mam-
malian host to evade the host immune response.
VSGs are expressed exclusively from subtelomeric
loci, and we have previously shown that telomere
proteins TbTIF2 and TbRAP1 play important roles
in VSG switching and VSG silencing regulation, re-
spectively. We now discover that the telomere du-
plex DNA-binding factor, TbTRF, also plays a criti-
cal role in VSG switching regulation, as a transient
depletion of TbTRF leads to significantly more VSG
switching events. We solved the NMR structure of
the DNA-binding Myb domain of TbTRF, which folds
into a canonical helix-loop-helix structure that is con-
served to the Myb domains of mammalian TRF pro-
teins. The TbTRF Myb domain tolerates well the bulky
J base in T. brucei telomere DNA, and the DNA-
binding affinity of TbTRF is not affected by the pres-
ence of J both in vitro and in vivo. In addition, we find
that point mutations in TbTRF Myb that significantly
reduced its in vivo telomere DNA-binding affinity also
led to significantly increased VSG switching frequen-
cies, indicating that the telomere DNA-binding activ-
ity is critical for TbTRF’s role in VSG switching regu-
lation.
INTRODUCTION
Trypanosoma brucei (T. brucei) is a protozoan parasite that
causes human African trypanosomiasis, which can be fatal
if left untreated. Current available drugs treating T. brucei
infection have severe side effects, and incidents of drug resis-
tance have been increasingly observed (1), making it imper-
ative to develop new generation anti-trypanosome drugs.
Bloodstream form (BF) T. brucei regularly switches its ma-
jor surface antigen, variant surface glycoprotein (VSG), in-
side its mammalian host to evade the host immune response
(2). This antigenic variation is a key pathogenesis mecha-
nism essential for a long-term T. brucei infection.
T. brucei has more than 2000 VSG genes and pseudo-
genes in its genome, mostly clustered at subtelomeric re-
gions (3,4). However, VSGs are exclusively expressed from
VSG expression sites (ESs) in a monoallelic fashion. BF
VSG ESs are polycistronic transcription units (PTUs) tran-
scribed by RNA polymerase I (5) and are located immedi-
ately upstream of the telomere (6). In the T. brucei Lister 427
strain used in this study, 15 ESs have been identified, all of
which have highly conserved DNA sequences (90% identi-
cal) and gene organizations (7). VSG is always the last gene
in any ES, located within 2 kb from the telomere repeats,
while the ES promoter is 40–60 kb upstream (7,8). At any
moment, only one ES is fully active, resulting in a single
type of VSG being expressed. This monoallelic VSG expres-
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sion ensures that the previously active VSG is no longer ex-
pressed after a VSG switching event, which is essential for
the effectiveness of antigenic variation.
VSG switching has several major pathways (9). In in situ
switching, the originally active ES is silenced while an origi-
nally silent one is expressed without DNA rearrangements.
Other major VSG switching pathways are homologous
recombination- (HR-) mediated. In crossover (CO) events,
part of the active ES, including the VSG gene, changes place
with that of a silent ES without losing any genetic informa-
tion. In gene conversion (GC) events, a silent VSG is copied
into the active ES to replace the active VSG gene, result-
ing in the loss of the originally active VSG and duplica-
tion of the newly active VSG. GC is the preferred mecha-
nism of VSG switching in the Lister 427 strain used in this
study (9). It can encompass only the VSG gene and its neigh-
boring regions (termed VSG GC) or the entire ES (termed
ES GC). In addition, the entire active ES can be lost, and
an accompanying in situ switch can give rise to ES loss +
in situ switchers (10–12). Several proteins involved in HR
have been shown to play important roles in VSG switching:
deletion of TbRAD51, TbRAD51-3 or TbBRCA2 leads to
decreased VSG switching frequencies (13–15). In contrast,
deletion of TOPO3 and RMI1 leads to more frequent
VSG switching (11,16).
The T. brucei telomere has been implicated in the regula-
tion of VSG expression and switching (17). We have previ-
ously shown that a telomere protein, TbRAP1, is required
for silencing subtelomeric VSGs (18,19). We have recently
shown that another telomere protein, TbTIF2, is important
for maintaining subtelomere/telomere integrity, and deple-
tion of TbTIF2 led to elevated VSG switching frequencies
(12). Therefore, telomere proteins are important for regu-
lation of VSG expression and VSG switching. A study by
Hovel-Miner et al. showed that T. brucei cells carrying ex-
tremely short telomeres (∼1.5 kb) exhibited an ∼10-fold
higher VSG switching frequency when compared to cells
with longer telomeres of 15 kb on average (20), indicating
that the telomere structure indeed plays an important role
in VSG switching regulation.
Our previous study identified a duplex telomere DNA-
binding factor, TbTRF, which interacts with both TbRAP1
(18) and TbTIF2 (12). While TbTRF is essential for main-
taining the terminal telomere structure (21), it does not af-
fect ES-linked VSG silencing in BF T. brucei cells (18). It is
intriguing whether TbTRF plays any important role in VSG
switching regulation. TbTRF has a similar domain struc-
ture as mammalian duplex telomere DNA-binding factors
TRF1 and TRF2, with an N-terminal TRF Homology
(TRFH) domain and a C-terminal Myb domain based on
sequence analysis (21). In mammalian TRF1 and TRF2,
the TRFH domain is required for homodimerization of
these factors that serve as an interaction platform to bind
other telomeric proteins including TIN2 and Apollo (22).
The Myb domain specifically binds to telomeric TTAGGG
repeats and serves to package both TRF1/2 and their
binding partners onto the telomere to form an integrated
protective structure (23–25). While our study has shown
that TbTRF has a strong duplex TTAGGG repeat bind-
ing activity (21), it remains to be confirmed whether its C-
terminal Myb domain mediates this direct interaction. Fur-
thermore, whether the Myb-mediated DNA-binding activ-
ity of TbTRF exerts any impact on VSG regulation is com-
pletely unknown.
Another interesting aspect regarding TbTRF and VSG
regulation involves the base J. In kinetoplastids, a heav-
ily modified base -D-glucosyl(hydroxymethyl)uracil, J, has
been identified to replace a small fraction of thymidines in
the genome (26,27). J is only present in the BF T. brucei
DNA but not in the DNA of procyclic form (PF) T. bru-
cei cells that normally reside in the mid-gut of their insect
vector, tsetse (Glossina spp.) (26). A relatively high level of
J is found in T. brucei telomeric DNA. Fourteen percent
of the T in the (CCCTAA)n strand and 36% of T in the
(TTAGGG)n strand is replaced by J (28). Silent VSG ESs
contain J, while the active ES does not (29). In addition to
its presence in the telomere, J appears to be also enriched
at tandem repeat regions of T. brucei genome (30). Further-
more, recent studies also showed that a small amount of J is
located at regions flanking RNA polymerase II (RNAP II)
PTUs throughout the T. brucei genome (31).
J’s function appears to be species-specific in kinetoplas-
tids. In T. brucei, J seems to be involved in regulation of tran-
scription elongation within certain RNAP II PTUs (32).
In Trypanosoma cruzi that causes Chagas disease, J is lo-
cated at the transcription initiation sites of RNAP II PTUs,
and loss of J led to elevated RNAP II transcription (33).
In Leishmania major that causes leishmaniasis, J is located
at the transcription termination sites of RNAP II PTUs,
and loss of J led to readthrough of RNAP II-mediated tran-
scription (32,34). With the enrichment of base J in T. brucei
telomeric DNA, it is intriguing whether the DNA-binding
Myb domain of TbTRF would interact with J-containing
TTAGGG repeats any differently from regular sequences.
Furthermore, whether such differences would have any im-
plication on VSG regulation is worth investigating.
To address these questions, we conducted a series of
structural and functional studies on the Myb domain of
TbTRF. The structure of the TbTRF Myb domain was
determined by nuclear magnetic resonance (NMR). The
DNA-binding activity of TbTRF, particularly the inter-
action between TbTRF and J-containing TTAGGG se-
quence, was characterized by in vitro binding assays and
in vivo Chromatin Immunoprecipitation (ChIP) experi-
ments. Structure-based mutational analysis identified a few
residues critical for Myb domain folding and its binding to
telomere. We found that a transient depletion of TbTRF led
to a 6-fold increase in VSG switching frequency. More im-
portantly, TbTRF Myb domain mutations that significantly
decreased TbTRF’s association with the telomeric DNA in
vivo also caused significantly more frequent VSG switching
events, indicating that the telomere DNA-binding activity
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The improved VSG switching assay enriches switchers by
passing cells through MACS column that binds a VSG2
monoclonal antibody (20). Detailed protocol can be found
in the supplemental materials.
ChIP
ChIP was performed as described in (35).
Quantitative reverse transcriptase-polymerase chain reaction
Quantitative RT-polymerase chain reaction (qRT-PCR)
was performed the same way as described in (12).
Electrophoresis mobility shift assay
Double-stranded oligos were prepared by standard anneal-
ing process after the two single-stranded DNA molecules
were mixed in equal molar ratio. The annealed double-
stranded oligos were then purified by gel electrophoresis be-
fore used in electrophoresis mobility shift assay (EMSA) or
NMR experiments. The regular or J-containing DNA (25
pmol) was incubated with increasing amount of TbTRF
Myb protein (0, 25, 50, 60, 75, 100, 120 or 130 pmol) in
buffer containing 20 mM HEPES pH 7.5, 40 mM KCl, 10
mM MgCl2, 10 mM CaCl2, 10 mM -mercaptoethanol,
0.25 mg/ml bovine serum albumin, 8% (v/v) glycerol at 4◦C
for 5 h and 37◦C for 15 min immediately before subjected
to 5% native polyacrylamide gel and run at 150 V in 0.25 ×
TBE buffer at 4◦C for 2 h. Gels were stained by EtBr and
scanned by ChemiDocTM XRS Imager (BioRad).
Protein expression and purification
The Myb domain of TbTRF (residues 281–382) was cloned
as a His6-tagged protein in a modified pET32 vector con-
taining the human rhinovirus (HRV) 3C protease cleav-
age site and without thioredoxin fusion. The mutants
(R298K, R298E, Q320S, Q321S, H346R, R348K, R348E
and R352K) were generated by site-directed mutagene-
sis (Finnzyme) and cloned into the same vector as wild-
type TbTRF. Wild-type and mutant TbTRF Myb domain
constructs were expressed in Escherichia coli BL21 (DE3)
cells at 25◦C for 8 h after induction by isopropyl--D-
thiogalactopyranoside at 0.75 mM concentration. Target
proteins were purified by affinity chromatography (HisTrap
HP, GE Healthcare). The His6 tag was removed by 3C cleav-
age and the untagged protein was further purified by size-
exclusion chromatography (Superdex 75, GE Healthcare).
NMR spectroscopy
The protein samples for NMR studies were concentrated
to ∼0.2 mM for titration experiments and ∼1.0 mM for
structural determinations in 100 mM potassium phos-
phate at pH 5.8. NMR spectra were acquired at 10◦C
on Varian Inova 500 or 750 MHz spectrometers. For
titration experiments, DNA oligos at 50 M were added
into the protein sample. Backbone and side chain res-
onance assignments were achieved by combination of
standard heteronuclear correlation experiments including
HNCO, HNCACB, CBCA(CO)NH and HCCH-TOCSY
using 15N/13C-labeled protein samples, and 1H 2D TOCSY
and NOESY experiments (36–38). Approximate interpro-
ton distance restraints were derived from 2D 1H-NOESY,
3D 15N-seperated NOESY and 3D 13C-seperated NOESY
spectra. Structures were calculated using the program CNS
(39). Statistics were summarized in Supplementary Table
S1. The coordinates of TbTRF Myb domain have been de-
posited to Protein Data Bank (PDB ID 2M9H). The struc-
ture figures were prepared using the CCP4mg package (40)
in CCP4.
Isothermal titration calorimetry
Isothermal titration calorimetry (ITC) was performed using
an iTC200 microcalorimeter (MicroCal Inc.) as described
previously (41–44). Additional details can be found in Sup-
plemental Materials.
Synthetic J-DNA oligos
The J-containing oligos are purchased from Fidelity Sys-
tems Inc. (http://www.fidelitysystems.com/).
Pulsed field gel electrophoresis
Pulsed field gel electrophoresis (PFGE) was performed as
described in (12).
RESULTS
Depletion of TbTRF increases VSG switching frequency and
changes VSG switching pattern
We previously found that TbTRF plays an essential role
in maintaining the telomere terminal structure (21), but
does not seem to affect subtelomeric VSG silencing (18).
However, whether TbTRF plays any role in VSG switch-
ing regulation is unknown. To test this possible function
of TbTRF, we introduced the pZJM-based (45) TbTRF
RNAi construct (21) into the HSTB261 cells developed for
VSG switching assays (16) to establish S/TRFi strains (S
for switching). As expected, induction of TbTRF RNAi by
doxycycline in S/TRFi cells led to a cell growth arrest by 24
h (Figure 1A, Supplementary Figure S1A) and a decrease
in TbTRF protein level (Figure 1B, Supplementary Figure
S1B).
In HSTB261, a blasticidin-resistance gene (BSD) was tar-
geted immediately downstream of the active ES promoter,
and a puromycin-resistance gene (PUR) fused with a Her-
pes simplex virus thymidine kinase (TK) gene was inserted
between the 70 bp repeats and the VSG2 gene in the same
active ES (Supplementary Figure S1C) (16). T. brucei cells
expressing TK are sensitive to ganciclovir (GCV), a nucleo-
side analog (46). Essentially all VSG switchers will lose the
PUR-TK expression and become GCV resistant. Therefore,
VSG switchers can be easily selected by GCV resistance. Be-
cause depletion of TbTRF leads to a cell growth arrest (21),
we induced the TbTRF RNAi for a short period of time
to enable subsequent recovery of VSG switchers. We found
that induction of TbTRF RNAi for 24 h followed by re-






/nar/article/42/20/12899/2903152 by guest on 19 M
ay 2021
























A7 - Dox 
A7 + Dox 
A8 - Dox 
A8 + Dox 
B1 - Dox 
B1 + Dox 














- ++ - +








































































Figure 1. A transient depletion of TbTRF led to an elevated VSG switching frequency. (A) S/TRFi cells experienced a transient growth arrest upon
induction of TbTRF RNAi by 100 g/ml doxycycline for 24 h. Growth curves were calculated from three independent experiments. A7, A8 and B1
are independent S/TRFi clones. In this and other figures, error bars represent standard deviation. (B) TbTRF protein level decreased upon induction of
TbTRF RNAi for 24 h. Western blotting was performed using whole cell lysate prepared from S/TRFi clone B1 cells and TbTRF (21) and EF-2 (Santa Cruz
Biotechnology, Inc.) antibodies. (C) VSG switching frequencies in S/v, S/TRFi B1 and S/TRFi+F2H-TbTRF cells with or without a transient TbTRF
RNAi induction. Average switching frequencies were calculated from at least three independent switching assays. Numbers on columns indicate P values
(unpaired t tests) when compared to the switching frequency in S/v cells. A P value less than 0.05 is considered significantly different. (D) VSG switching
mechanism distribution in S/TRFi B1 cells under the induced and uninduced conditions. The total number of switchers characterized is indicated above
each column. GC, gene conversion; CO, crossover.
and a growth arrest for 24 h followed by a recovery of the
TbTRF protein level and the growth (Figure 1A and B). The
recovered TbTRF RNAi cells exhibited growth arrest again
when induced by doxycycline repetitively (Supplementary
Figure S1A), indicating that the recovered population re-
tained the ability of RNAi induction.
Before the VSG switching assay, cells were kept under se-
lection with blasticidin and puromycin to ensure uniform
expression of VSG2 in the population. At the beginning of
the VSG switching assay, blasticidin and puromycin were re-
moved from the medium to allow switchers to arise. Three
independent S/TRFi clones were incubated with or without
doxycycline for 24 h followed by removal of doxycycline by
extensive cell washing and cell recovery. Induced S/TRFi
cells typically took ∼48 h to fully recover, while the unin-
duced cells grew normally. Eventually, all cells were grown
for the same number of population doublings to allow a fair
comparison of VSG switching frequencies between induced
and uninduced cells. A small fraction of cells was plated
in the absence of GCV to determine the plating efficiency.
Initially, we plated 0.5 million cells after each switching as-
say and found that a transient depletion of TbTRF led to
a significant increase in the VSG switching frequency (Sup-
plementary Figure S1D, S1E), indicating that TbTRF sup-
presses VSG switching.
We attempted to isolate sufficient switchers from S/TRFi
cells to determine the VSG switching mechanisms. How-
ever, this original switching method is very inefficient and
we could only obtain limited number of switchers in each
assay. We therefore adopted the modified switching assay
by enriching switchers using MACS beads that bind a mon-
oclonal VSG2 antibody (20). Cells expressing VSG2 were
retained by the MACS column, while switchers were en-
riched in the flow-through fraction and were plated in the
presence of GCV for subsequent selection. This modified
switching method allowed us to isolate ∼100 switchers un-
der each condition, which greatly increased the assay effi-
ciency. Using the MACS switching assay, we examined the
VSG switching frequencies and mechanisms in HSTB261
cells carrying an empty RNAi vector (S/v) (12) and S/TRFi
clone B1 cells under induced and uninduced conditions. We
grew cells for approximately the same number of popula-
tion doublings in both the original and the MACS switching
assays to ensure that the results were comparable. We con-
firmed that a transient depletion of TbTRF led to a 6-fold
higher VSG switching frequency than that in S/v cells, while
uninduced S/TRFi cells exhibited a similar VSG switch-
ing frequency as S/v cells (Figure 1C, Supplementary Fig-
ure S1F). S/v cells had a similar VSG switching frequency
as reported in HSTB261 cells (11,16). Inducing the expres-
sion of an ectopic F2H-tagged WT TbTRF allele in S/TRFi
cells (Supplementary Figure S1H) also complemented the
slow growth (Supplementary Figure S1G) and the elevated
VSG switching frequency phenotypes (Figure 1C). There-
fore, WT TbTRF suppresses subtelomeric VSG switching.
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shorten telomere length dramatically (21). We confirmed
that telomere length did not change significantly within the
short frame of time when TbTRF was depleted (Supple-
mentary Figure S1I), indicating that elevated VSG switch-
ing frequency is not due to extremely short telomere lengths.
However, extremely short telomere would presumably bind
very few TbTRF proteins, which would in turn result in in-
creased VSG switching frequency, as observed in telomerase
null cells with short telomeres (20).
Using the MACS switching assay, we obtained ∼100 or
more VSG switchers under each assay condition. Analyzing
a larger number of VSG switchers allowed us to reveal the
typical VSG switching patterns more accurately. By charac-
terizing the genotype and marker expression status, we can
determine the VSG switching mechanisms (Supplementary
Figure S1C) as described previously (11,12,16). By select-
ing switchers with various antibiotics and PCR analyses us-
ing VSG- or BSD-specific primers, we determined that be-
fore TbTRF RNAi induction, most switchers (∼85%) were
VSG GC events, while a considerable number of switch-
ers were ES GC or ES loss + in situ events (∼14%) (Fig-
ure 1D). In contrast, after a transient depletion of TbTRF,
ES GC/ES loss + in situ events became predominant (65%),
while only ∼33% of all switchers were VSG GC events (Fig-
ure 1D). In addition, in situ switchers were extremely rare in
uninduced S/TRFi cells (none in examined VSG switchers),
but increased to 1.5% in TbTRF-depleted cells. Therefore,
TbTRF influences the VSG switching mechanisms.
The Myb domain of TbTRF adopts the canonical helix-turn-
helix structure
TbTRF binds to the duplex TTAGGG telomere repeats di-
rectly (21). This affinity has been assigned to its C-terminal
region that shares high sequence similarity to the Myb do-
mains in mammalian TRF proteins (47). Myb domains are
small structural modules of 50–60 residues that are com-
monly found in DNA-binding proteins (48). The structures
of mammalian TRF Myb domains reveal a conserved fold
of three-helix bundle with the classical helix-turn-helix mo-
tif as the DNA-binding element (23,49,50).
To further delineate the role of the TbTRF Myb domain
in VSG switching regulation, we first solved the NMR struc-
ture of this region. While the core region of the Myb do-
main consists of only 50–60 residues, a longer construct of
TbTRF Myb extending about 20 residues more on both
the N- and C-termini is necessary to yield soluble pro-
tein. The heteronuclear single quantum correlation (HSQC)
spectrum of 15N-labeled TbTRF Myb domain showed an
excellent dispersion pattern typical of a well-folded protein
(Figure 2A). The structure was determined with a conven-
tional multidimensional heteronuclear NMR method with
the statistics summarized in Supplementary Table S1. The
final 20 structures superimpose well, with root-mean-square
deviation (RMSD) of 0.6 Å for the backbone atoms in the
core region (Figure 2B). The N- and C-terminal extensions,
while critical for solubility of this domain, are highly flexi-
ble as they show few medium- and long-range nuclear over-
hauser effect signals.
The overall structure of TbTRF Myb domain follows
the canonical three-helix bundle architecture, with the sec-
ond and third helix forming the helix-turn-helix motif for
DNA binding. This TbTRF Myb structure is very similar
to the human TRF1 and TRF2 Myb structures, especially
the three core helices with RMSD of 0.6 and 0.83 Å, respec-
tively (Figure 2C). However, the loops connecting these he-
lices adopt quite different conformations in TbTRF from
that of human TRF1 and TRF2, probably due to their in-
trinsic flexibility (Figure 2C).
TbTRF Myb is stabilized by an extensive hydropho-
bic core consisting of a few conserved residues including
I309, L313, L343 and W347 when compared to mammalian
TRFs (Figure 2D). Another interesting observation about
TbTRF Myb is the pH sensitivity of its folding. The HSQC
spectrum showed significant deterioration when buffer pH
was adjusted from 5.8 to 6.5 (data not shown). Close inspec-
tion of the structure revealed that H346, the only residue in
TbTRF Myb with its imidazole side chain of pKa around
6.5, is likely the major factor for this pH sensitivity. H346,
located on the third helix, forms a salt bridge interaction
with D306 on the first helix (Figure 2D). This interaction
is critical for packing of these two helices to form the three-
helix bundle. Deprotonation of H346 when buffer pH arises
above 6.5 likely weakens this interaction and may lead to
partial unfolding of TbTRF Myb.
TbTRF Myb domain binds to both regular and J-containing
telomeric DNA
The direct interaction of the TbTRF Myb do-
main with telomeric DNA repeats was first char-
acterized by EMSA. Purified TbTRF Myb peptide
readily formed a complex with a ‘double-repeat’
DNA oligo that contained two telomeric repeats (5′
GGCGCGCTTAGGGTTAGGGTTACCGCCCG 3′)
(Supplementary Figure S2A). We also used ITC to directly
measure the binding affinity (Kd) between TbTRF Myb
and its DNA substrate. Our data showed that TbTRF Myb
bound to single- (5′ GGGGCCTTTAGGGTTATCCGCC
3′) and double-repeat (same sequence as used in EMSA)
DNA oligos with comparable affinities at Kd of ∼20 M
(Figure 3A, Supplementary Figure S2B). In summary,
these biochemical data confirm that TbTRF Myb can
directly bind to telomeric TTAGGG repeats.
A considerable amount of thymidine in the BF T. brucei
telomeric DNA is replaced by the base J (28). J is absent in
the PF T. brucei DNA, and TbTRF associates with telom-
eric DNA in both BF and PF cells (21), indicating that the
TbTRF DNA-binding activity is not abolished by J or re-
quires J. However, it is unknown whether the TbTRF Myb
domain binds J-containing telomeric DNA the same way as
it binds the regular telomeric sequence.
To directly test whether J affects the DNA-binding ac-
tivity of the TbTRF Myb domain, we first constructed
a synthetic J-containing duplex oligo with the sequence
of TJAGGG/AATCCC to represent a single-repeat DNA
substrate. The presence of J in this oligo was confirmed by
mass spectroscopy (Supplementary Figure S3A). ITC anal-
ysis revealed that the binding affinity (Kd) of TbTRF Myb
to the J-containing oligo is ∼12 M, comparable to that of
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Figure 2. Structure of TbTRF Myb domain. (A) The 1H-15N HSQC spectrum of 15N-labeled TbTRF Myb domain at pH 5.8. A selected region of the
spectrum enclosed by a framed rectangle is expanded to show the detail of residue assignments. (B) Ensemble of the final 20 lowest energy structures of
TbTRF overlaid on the backbone. The three helices H1–H3 are drawn as ribbons. (C) Structural alignment of TbTRF Myb domain (light blue) with that
of human TRF1 (light yellow, PDB ID 1ITY) and TRF2 (gold, PDB ID 1VF9). The TbTRF Myb domain is the energy minimized average structure
generated from the ensemble. (D) The hydrophobic core and the D306-H346 salt bridge in the TbTRF Myb structure.
Lastly, we performed EMSA analysis using the same J-
containing single-repeat DNA as a substrate. The partially
purified bacteria-expressed TbTRF myb domain showed
a similar DNA-binding activity regardless of whether the
telomeric DNA substrate contained J or not (Supplemen-
tary Figure S3B). These results confirm that the presence of
J in the telomeric DNA does not affect its interaction with
the TbTRF Myb domain in vitro.
To better quantify the telomeric DNA-binding activity
of TbTRF in vivo, we performed a ChIP analysis in BF
cells treated with or without DMOG, a cell-permeable in-
hibitor of dioxygenase (51). It has been shown that treat-
ing BF T. brucei cells with 0.5 mM DMOG in DMSO for
6 days resulted in 80% of decrease in cellular J (52). We
performed TbTRF ChIP in the presence and absence of
DMOG and found that similar amount of TbTRF was as-
sociated with the telomeric DNA under both conditions
(Figure 3B). To confirm that treating cells with DMOG re-
moved most telomeric J, we performed a Southern analysis.
It has been shown that the active VSG ES does not con-
tain J, while silent ESs do (29), and J modification prevents
PstI digestion (53,54). Indeed, we found that in the VSG2-
expressor, the active VSG2 gene was fully digested by PstI
(Supplementary Figure S3C, S3D). However, in the VSG9-
expressor, the same VSG2 gene, now silent, was only par-
tially digested by PstI (Supplementary Figure S3C, S3D).
Treating cells with 0.5 mM DMOG for 6 days allowed the
silent VSG2 locus to be fully digested with PstI, indicating
that DMOG successfully removed the J modification. Treat-
ing cells with DMSO (as a control) did not have any effect
on J (Supplementary Figure S3C). In addition, as expected,
DMOG treatment did not affect cell growth (Supplemen-
tary Figure S3E), because J is not essential for T. brucei
growth (55). Therefore, J modification does not affect the
telomeric DNA-binding activity of TbTRF.
Perturbing the TbTRF Myb domain significantly decreases
its DNA-binding activity
NMR titration experiments were performed to iden-
tify TbTRF Myb residues critical for DNA bind-
ing. A double-repeat DNA oligo with sequence 5′
GGCGCGCTTAGGGTTAGGGTTACCGCCCG 3′
was titrated into 15N-labeled TbTRF Myb and the result-
ing HSQC spectrum was compared to that of protein alone
(Figure 4A). Overall the DNA-titrated HSQC spectrum
showed significant difference as compared to the TbTRF
Myb-only spectrum, confirming that there was a direct
interaction between TbTRF Myb and the double-repeat
oligo. The severe broadening of many cross peaks in the
titrated spectrum was probably due to the large size of the
TbTRF Myb–DNA complex formed (∼80 kDa with two
TbTRF Myb domains associated with the double-repeat
DNA oligo).
While the broadening hindered our effort to pinpoint key
DNA-binding residues, we proceeded to generate a model
of TbTRF Myb in complex with the telomeric DNA us-
ing the human TRF1 Myb-DNA structure as a reference
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5’ – GGTTAGGGTTAGG – 3’
3’ – CCAATCCCAATCC – 5’
5’ – GGTJAGGGTTAGG  –3’
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Figure 3. Characterization of TbTRF binding to telomeric DNA. (A) ITC-based measurement of TbTRF Myb–DNA interaction using regular (left) and
J-containing oligo (right). Each measurement was repeated three times. Values of binding affinity (Kd), stoichiometry (N) and binding enthalpy (H) with
standard deviation are shown. (B) J does not influence the binding of TbTRF on telomeric DNA in vivo. ChIP was performed using TbTRF antibody
(21) in cells grown in normal medium, medium with Dimethyl sulfoxide (DMSO) or medium with 0.5 mM Dimethyloxalylglycine (DMOG) dissolved in
DMSO. Southern analyses using the TTAGGG repeat (left) or the 50 bp repeat (right) probe were performed to hybridize the ChIP products. Southern
blots were exposed to phosphorimager screens and the percentage of enrichment was calculated by dividing the ChIP signal by the input signal. Average
values were calculated from at least three independent experiments.
man TRF1 Myb with its third helix inserted into the major
groove of telomeric DNA, mimicking the canonical Myb–
DNA-binding mode (Figure 4B). In this model, the con-
served R348 was well positioned to make sequence-specific
contact with the G-C triplet in the telomeric repeat. Its cor-
respondence in human TRF1, R425, has been shown to
make similar sequence-specific interactions with the telom-
eric DNA substrate (49). Furthermore, our model showed
that Q320 and Q321, two TbTRF Myb-specific residues not
highly conserved in the mammalian system, were also in
close proximity to make contact with the sugar-phosphate
backbone of DNA substrate. Based on our NMR data and
modeling observations, we selected these residues (Q320,
Q321 and R348) and three additional residues (R298, H346
and R352) for structure-based biochemical and functional
studies. H346 is included because the salt bridge interaction
it forms with D306 as shown by the NMR structure could
play an essential role in stabilizing the folding of TbTRF
Myb and facilitating its DNA-binding activity. R298 and
R352 were also included because the flexible N- and C-
terminal loops have been shown to contact DNA substrates
by previous studies (49), although our model cannot pre-
cisely confirm this.
Additionally we also constructed a model of the TbTRF
Myb domain in complex with the J-containing telom-
eric DNA (Figure 4C). The J-base was ‘grafted’ onto
the TbTRF Myb–DNA model by superimposing a J-
containing oligo (PDB ID 308D) onto the existing reg-
ular DNA in the model. The base J replacing the T in
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Construct WT R298K R298E Q320S Q321S H346R R348K R348E R352K
Kd (mM) 0.02±0.002 No No 1.92±1.30 0.69±0.48 0.29±0.14 No No 0.14±0.05
Figure 4. Key DNA-binding residues within TbTRF Myb domain.
(A) Superposition plot of the 1H–15N HSQC spectra of TbTRF alone
and TbTRF titrated with a double-repeat DNA oligo pair in 1:0.5
molar ratio. (B) Model of TbTRF Myb domain bound to telomeric
DNA generated by superimposing TbTRF Myb onto human TRF1
Myb–DNA complex structure (PDB ID 1IV6). (C) Model of TbTRF
Myb bound to a J-containing DNA. The J-DNA (PDB ID 308D)
is superimposed onto regular DNA in the TbTRF Myb–DNA com-
plex structure of (B). (D) Binding affinity (Kd) of WT and mu-
tant TbTRF Myb domain with a duplex telomeric oligo of sequence
5′ GGCGCGCTTAGGGTTAGGGTTACCGCCCG 3′ as measured by
ITC. (E) ChIP analyses of TbTRF myb point mutants. ChIP experi-
ments were performed using TbTRF antibody (21) or normal rabbit im-
munoglobulin G in cells expressing the TbTRF Myb point mutant as
the only TbTRF allele. Southern hybridizations were performed using the
TTAGGG repeat probe or the 50 bp repeat probe as a control (Supple-
mentary Figure S5C). Southern blots were exposed to a phosphorimager
screen and signal intensities were quantified. The percentage of enrichment
was calculated by dividing the ChIP signal by the input signal. The aver-
age was calculated from at least three independent experiments. P values
(unpaired t tests) of TbTRF ChIP result between each mutant and TbTRF
+/- are listed on each column.
DNA major groove and was in the vicinity of the loop
connecting the second and third helix but sufficiently away
from the most critical DNA-binding residues on the third
helix. The base J replacing the T in the complementary
AATCCC strand was positioned completely away from the
Myb-binding site and unlikely to exert any influence. Thus,
our model supports our binding studies that the presence
of J is unlikely to exert any direct influence on the DNA-
binding activity of the TbTRF Myb domain.
Focusing on the six residues identified by NMR titration
studies and supported by our structural model, we gener-
ated a series of mutant TbTRF Myb constructs (Figure 4D).
EMSA (Supplementary Figure S4A) and ITC experiments
(Supplementary Figure S4B) were performed to character-
ize the DNA-binding affinities of these mutants in vitro. In-
deed, mutations targeting the highly conserved R348 such
as R348E and a milder perturbation of R348K completely
abolished the DNA binding. Similar effect was also ob-
served for the N-terminal R298 mutations, suggesting that
R298 directly participates in DNA binding. However, mu-
tations targeting the TbTRF Myb-specific residues such as
Q320, Q321 and H346 did not abolish the DNA binding,
although the binding was significantly weakened.
To further characterize the mutant TbTRF DNA-
binding activity in vivo, we introduced these point mutations
into T. brucei cells. In the TbTRF single knockout (sko)
background, we replaced the remaining endogenous WT
TbTRF allele with the mutant TbTRF allele carrying an N-
terminal Ty1 tag. We could not obtain T. brucei strains that
only expressed the TbTRF R298E or TbTRF R348E mu-
tant, suggesting that these strong mutational perturbations
completely abolished the in vivo telomeric DNA-binding ac-
tivity of TbTRF and were not viable. All other TbTRF mu-
tants were expressed equally in western analysis at a level
similar to that in TbTRF sko cells (Supplementary Figure
S5A), and sequencing analysis confirmed the mutation in
each mutant strain. Among TbTRF Myb mutants, H346R
exhibited a mild slow growth phenotype, while R298K and
R348K had a slow growth phenotype that is even milder
(Supplementary Figure S5B).
We performed TbTRF ChIP analysis in the TbTRF
mutant strains. H346R had the weakest telomeric DNA-
binding activity, while R298K and R348K also exhibited
weaker than WT telomeric DNA-binding activities (Fig-
ure 4E, Supplementary Figure S5C), and the differences be-
tween these three mutants and WT TbTRF are significant.
In contrast, Q320S, Q321S and R352K mutants are asso-
ciated with the telomeric DNA at similar levels to that of
the WT (Figure 4E, Supplementary Figure S5C), indicating
that the telomeric DNA-binding activities in these TbTRF
Myb mutants were not significantly affected in vivo.
To examine whether VSG silencing is affected in TbTRF
myb mutants, we performed qRT-PCR to estimate the
steady-state mRNA levels of several ES-linked VSGs and
several control genes including TbTERT, TbRPS15 and
rRNA in TbTRF mutants and sko cells. In most cases, we
did not observe higher VSG mRNA levels in TbTRF mu-
tants than in sko cells except that elevated VSG3 and VSG13
mRNA levels were detected in H346R/- and R348K/- cells,
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decreasing the DNA-binding activity of TbTRF did not af-
fect VSG silencing globally.
TbTRF Myb domain mutants with weakened DNA binding
show increased VSG switching frequencies
We found that a transient depletion of TbTRF led to an in-
creased VSG switching frequency. To further test whether
the telomeric DNA-binding activity of TbTRF is essen-
tial for VSG switching regulation, we introduced TbTRF
Myb mutants that significantly reduced the telomere DNA-
binding activity (H346R, R298K and R348K) in HSTB261
cells and deleted the remaining WT TbTRF allele. As a con-
trol, we also introduced the Q320S mutant that did not af-
fect TbTRF DNA-binding activity into HSTB261. Western
analysis confirmed the expression of the TbTRF mutants in
these cells (Supplementary Figure S5E). Southern and PCR
analyses also confirmed the TbTRF genotype, and sequenc-
ing analysis verified each mutant (data not shown).
We performed the VSG switching analysis in TbTRF myb
domain mutants using MACS to enrich the VSG switch-
ers. We found that TbTRF sko strain exhibited a similar
VSG switching frequency as the S/v cells (Figures 1C and
5A), indicating that a single allele of TbTRF was suffi-
cient for its function in VSG switching regulation. Interest-
ingly, S/H346R had a significantly increased (3.3-fold) VSG
switching frequency than S/TRF sko (Figure 5A). In addi-
tion, S/R298K and S/R348K cells showed a mild but sig-
nificant increase in VSG switching frequency (1.6 fold) (Fig-
ure 5A). In contrast, S/Q320S behaved similarly as S/TRF
sko cells. Therefore, the H346R mutant that significantly re-
duced the association of TbTRF with the telomeric DNA
in vivo led to significantly more VSG switching. R298K
and R348K mutants that mildly affected the in vivo DNA-
binding activity also mildly increased VSG switching fre-
quency. While the Q320S mutant that did not affect DNA
binding in vivo did not affect VSG switching, either, indicat-
ing that the telomere DNA-binding activity is critical for the
role of TbTRF in VSG switching regulation.
We further characterized the VSG switching mechanisms
in S/TRF sko and TbTRF myb mutants. Similar to S/v
cells, S/TRF sko cells had predominantly VSG GC events
(84%) and a considerable percentage of ES GC/ES loss + in
situ events (14%). In TbTRF mutants that exhibited more
frequent VSG switching, we observed a decreased percent-
age of VSG GC events (48–56%) and an increased percent-
age of ES GC/ES loss + in situ events (40–48%), which was
similar to that in TbTRF-depleted cells, although the ef-
fects were to a lesser degree (Figures 1D and 5B). In addi-
tion, we observed an increase in in situ switchers in TbTRF
mutants (from 0% in sko cells to 1.8–5.3% in TbTRF mu-
tants), which is similar to induced S/TRFi cells (Figure 1D).
Therefore, the DNA-binding activity of TbTRF is impor-
tant for its function in VSG switching regulation.
To verify that VSG switchers were correctly assigned with
corresponding switching mechanisms, we randomly picked
switchers from various TbTRF genetic backgrounds and
performed PFGE and Southern analyses using VSG2, BSD
and the newly activated VSG probes. Supplementary Figure
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Figure 5. TbTRF myb mutations that decreased the telomere DNA-
binding activity also increased the VSG switching frequencies. (A) VSG
switching frequencies in S/TRF sko and S/TRF mutants. Average values
were calculated from at least three independent experiments. P values (un-
paired t tests) comparing S/TRF sko and S/TRF mutants are indicated
on each column. (B) VSG switching mechanism distribution in S/TRF
sko and S/TRF mutants. The total number of switchers characterized is
indicated above each column.
DISCUSSION
TRF is an essential telomeric protein conserved among a
number of species from the T. brucei protozoan to human.
In mammalian cells, TRF1 and TRF2 are two key compo-
nents of the Shelterin complex that protects the chromo-
some end (57). Removal of TRF2 from telomeres led to
ATM/p53-dependent ligase IV-mediated NHEJ of telom-
ere ends (58–60). Removal of TRF1 from telomeres led to
telomere elongation (61) and fragile telomeres (62). Both
TRF1 and TRF2 contain a highly conserved C-terminal
Myb domain that directly binds to the telomeric DNA,
which enables TRFs to serve as architectural factors and to
nucleate the Shelterin complex at the telomere (63). Struc-
tural analysis of mammalian TRF myb domains revealed
that these structural modules use a conserved helix-turn-
helix motif for specific binding to the TTAGGG telomeric
sequence (49,56).
T. brucei is a protozoan parasite that undergoes antigenic
variation through VSG switching to evade the host immune
response (2). Because the repertoire of over 2000 VSG genes
in T. brucei are located at subtelomeres (4), the telomere
structure and associated proteins have long been speculated
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data have been reported to support this hypothesis (12,20).
TbTRF is the first telomere protein identified and found to
be essential for maintaining the telomere terminal structure
in T. brucei (21). The role of TbTRF in VSG switching has
not been investigated, although it is not required for sub-
telomeric VSG silencing (18).
Here we have conducted structural and functional stud-
ies to delineate the role of TbTRF and its Myb domain in
VSG switching. First, we found that a transient depletion of
TbTRF led to significantly more VSG switchers and most
of these arose from ES GC/ES loss + in situ events. This
confirms a definitive role of TbTRF in suppression of VSG
switching. Although a transient depletion of TbTRF led to
a growth arrest, this arrest is short-term and fully reversible,
excluding the possibility that the observed more frequent
VSG switching is a ‘death phenotype’. RNAi has been used
to show that several essential proteins are important in regu-
lation of VSG switching through apparently different mech-
anisms (12,35,64,65). Furthermore, a simple slow growth
is not expected to result in more frequent VSG switch-
ing, because deletion of TbMRE11 led to significantly slow
growth, but did not affect VSG switching (66).
Second, our structural data show that the TbTRF
Myb domain adopts the canonical helix-turn-helix DNA-
binding motif shared by all Myb domains. The three core
helices are tightly packed together by a cluster of hydropho-
bic residues. This core region superimposes very well with
mammalian TRF1/2 Myb domain structures, suggesting
a highly conserved structural module for sequence-specific
binding to telomeric DNA repeats. However, the loops con-
necting the three helices and both the N- and C-termini of
Myb region are highly flexible, with little sequence identity
between TbTRF and mammalian TRF1/2.
Furthermore, our in vitro data show that the TbTRF
Myb domain binds to telomeric sequences containing the
bulky J-base with similar affinity as to normal telomeric se-
quences. Structure-based modeling suggests that although
J is a bulky modification, it is not located at the interface
of DNA and TbTRF interaction. Thus, J is unlikely to af-
fect TbTRF binding. Our in vivo ChIP analysis further con-
firmed that TbTRF associated with the telomeric DNA at
equal efficiency whether the substrate contained J or not.
There have been no reports on whether mammalian
TRF1/2 can bind to J-containing telomeric DNA. A pre-
vious study showed that human TRF1 could be expressed
in PF T. brucei cells and was located at the telomere that
does not have J modification (67). However, human TRF1,
when expressed in BF T. brucei cells where the DNA is mod-
ified by J, is not located at the telomere (67). Presumably,
the presence of J in BF telomeres interfered with efficient
binding of human TRF1, although the possibility that other
telomere factors are involved in such reduced TRF1 binding
cannot be ruled out. Further studies, such as in vitro mea-
surement of the binding affinity of mammalian TRF1/2
Myb to J-DNA and in vivo ChIP assays, are needed to fully
address this question.
We generated a series of structure-based mutations within
the TbTRF Myb domain to abolish or weaken its DNA-
binding affinity. Three assays, including the in vitro EMSA
and ITC, together with the in vivo ChIP assay, were used
to characterize the effects of individual mutations on the
DNA-binding activity of TbTRF. VSG switching assays
were also carried out to correlate the DNA-binding affinity
of these TbTRF mutations to their VSG regulation func-
tion. For all mutations except H346R (discussed below), re-
sults from all these assays are consistent or at least show
the same trend of effects. Specifically, R298E and R348E
abolished in vitro DNA-binding activity, and we could not
obtain any cells expressing these mutant alleles, suggest-
ing that they also abolish DNA binding in vivo. R298K
and R348K abolished in vitro DNA-binding activity and
showed significantly reduced telomere association and in-
creased VSG switching in vivo, while Q320S, Q321S and
R348K only weakened in vitro DNA-binding activity and
exhibited subtle and insignificant effects on their in vivo
telomere association and VSG switching.
Therefore, all tested Myb mutants except H346R showed
milder effects in vivo than in vitro. Such mild in vivo effect
is likely due to different TbTRF constructs used in in vitro
and in vivo methods. TbTRF homodimerizes through its
TRFH domain, and this dimerization is critical for its in
vivo telomere DNA-binding activity (21), because at least
two Myb domains are required for efficient DNA recogni-
tion (68). In addition, TbTRF interacts with other telom-
ere proteins in live cells (12,18), which may also influence
its in vivo telomere DNA-binding activity. Our in vitro stud-
ies were performed with the Myb domain alone, which is
not expected to dimerize, while our in vivo assays were per-
formed with full-length TbTRF proteins that are capable
of dimerization. Therefore, it is possible that dimerization
of TbTRF mutants, as well as its interaction with other
telomeric factors, may serve to recover some of the mutants’
DNA-binding activity in vivo.
H346R is unique among the tested mutants, as it showed
a stronger phenotype in vivo than in vitro. Its in vitro DNA-
binding affinity is stronger than that of R298K and R348K
(weakened versus abolished), yet its ChIP enrichment is
weaker and its VSG switching frequency higher than the
latter two mutants. This is likely because of the unique role
of H346 when compared to other residues. As shown by
our NMR data, H346 is critical for the proper folding of
TbTRF Myb domain, although it does not directly interact
with the telomeric DNA. Thus, the stronger in vivo effect of
H346R was probably caused by the loss of proper folding
of full-length TbTRF when the Myb domain structure was
compromised.
In summary, the TbTRF Myb mutations that abolished
(R298K and R348K) or weakened (H346R) DNA bind-
ing in in vitro analyses led to reduced in vivo DNA binding
when analyzed by ChIP, enhanced VSG switching by 1.6–
3.3 fold and increased the proportion of ES GC/ES loss +
in situ switchers, demonstrating that the function of TbTRF
in VSG switching regulation depends on the structural in-
tegrity and telomere DNA-binding activity of its Myb do-
main.
TbTRF plays an essential role in maintaining the telom-
ere terminal structure and is a functional homolog of mam-
malian TRF2 (21). Similar to loss of TRF2 (58–60), loss
of TbTRF could result in telomere fusions and subsequent
breakage-fusion-bridge cycle, which often result in large ter-
minal chromosome deletions (69). Since loss of VSG ex-
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only switchers that express a different VSG can survive
the TbTRF-depletion-induced loss of the active VSG gene.
However, chromosome end fusions have not been detected
in T. brucei. It is unknown whether NHEJ exists in this pro-
tozoan, because no DNA Ligase IV homolog has been iden-
tified in T. brucei (71), although Ku homologs have been
identified (72,73).
Recent studies showed that increased DNA damages in
the active ES lead to greatly increased VSG switching fre-
quencies (10,74), and damages downstream of the active
VSG gene often lead to ES loss (10). It is possible that
TbTRF has a conserved function in telomere DNA repli-
cation as human TRF proteins (62,75). In this case, loss
of TbTRF could lead to stalled DNA replication forks in
telomere repeats, which would cause increased damages at
telomeres that contribute to increased VSG switching. Ad-
ditional investigations are necessary to examine whether de-
pletion of TbTRF would lead to elevated DNA damages at
telomeres and subtelomeres.
TbTRF plays an important role in VSG switching regula-
tion, a critical aspect of antigenic variation in T. brucei. The
function of TbTRF is different from that of TbRAP1, which
is a TbTRF-interacting factor and is essential for subtelom-
eric ES-linked and metacyclic VSG silencing in both BF and
PF T. brucei cells (18,19). Therefore, although TbTRF inter-
acts with TbRAP1 (18), these two telomere proteins appear
to have independent functions in antigenic variation regu-
lation. In contrast, depletion of another telomere protein,
TbTIF2, also leads to more frequent VSG switching and
more ES GC/ES loss + in situ switching events (12). Because
TbTRF is the telomere DNA-binding protein and TbTIF2
is presumably recruited to the telomere by interacting with
TbTRF, it is possible that depletion of TbTRF resulted in
removal of TbTIF2 from the telomere, which in turn leads
to elevated VSG switching frequency (12). Further inves-
tigations of how TbTIF2 is recruited to the telomere will
help answer this question. TbTRF appears to interact with
TbTIF2 more strongly than with TbRAP1 in both yeast
2-hybrid and co-IP experiments (12,18). Hence, it is likely
that TbTRF and TbTIF2 function in the same pathway in
regulating VSG switching. However, it is necessary to ex-
amine VSG switching frequencies and mechanisms in cells
depleted of both TbTRF and TbTIF2 to determine defini-
tively whether the two proteins work in the same pathway.
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